DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Pivotal 72-week trial behind Zepbound's FDA approval. Average 20.9% body weight loss at the 15 mg dose.
SURMOUNT-1 randomized 2,539 adults with overweight or obesity (without T2D) to tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. Mean weight loss: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg) vs 3.1% placebo. 91.0% of patients on 15 mg achieved ≥5% weight loss. Pivotal trial supporting Zepbound's FDA approval. NEJM 2022.